Comparative antimicrobial activities of the newly synthesized quinolone WQ-3034, levofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 2, 2000, Pages 283-286

  Tomioka, Haruaki ^a   Sato, Katsumasa ^a   Kajitani, Hiroko ^a   Akaki, Tatsuya ^a   Shishido, Shinji ^b  

^a SHIMANE UNIVERSITY   (Japan)

^b National Sanatorium Matsue Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1 (6 AMINO 3,5 DIFLUORO 2 PYRIDYL) 8 CHLORO 6 FLUORO 1,4 DIHYDRO 7 (3 HYDROXY 1 AZETIDINYL) 4 OXO 3 QUINOLINECARBOXYLIC ACID; CIPROFLOXACIN; LEVOFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFALAZIL; RIFAMPICIN; SPARFLOXACIN; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; GROWTH INHIBITION; HUMAN; HUMAN CELL; INCUBATION TIME; LUNG ALVEOLUS CELL TYPE 2; MACROPHAGE; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM AVIUM; MYCOBACTERIUM INTRACELLULARE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL;

4-QUINOLONES; AMINOPYRIDINES; ANTI-INFECTIVE AGENTS; ANTITUBERCULAR AGENTS; CIPROFLOXACIN; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM AVIUM COMPLEX; MYCOBACTERIUM TUBERCULOSIS; OFLOXACIN; QUINOLONES; RIFAMYCINS;

EID: 0033978267     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.2.283-286.2000     Document Type: Article

References (23)

1. Akaki, T., K. Sato, T. Shimizu, C. Sano, H. Kajitani, S. Dekio, and H. Tomioka. 1997. Effector molecules in expression of the antimicrobial activity of macrophages against Mycobacterium avium complex: roles of reactive nitrogen intermediates, reactive oxygen intermediates, and free fatty acids. J. Leukoc. Biol. 62:795-804.
2. Alangaden, G. J., and S. A. Lerner. 1997. The clinical use of fluoroquinolones for the treatment of mycobacterial diseases. Clin. Infect. Dis. 25:1213-1221.
3. Bermudez, L. E., and J. Goodman. 1996. Mycobacterium tuberculosis invades and replicates within type II alverolar cells. Infect. Immun. 64:1400-1406.
4. Chan, J., Y. Xing, R. S. Magliozzo, and B. R. Bloom. 1992. Killing of virulent Mycobacterium tuberculosis by reactive nitrogen intermediates produced by activated murine macrophages. J. Exp. Med. 175:1111-1122.
5. Chien, S.-C., M. C. Rogge, L. G. Gisclon, C. Curtin, F. Wong, J. Natarajan, R. R. Williams, C. L. Fowler, W. K. Cheung, and A. T. Chow. 1997. Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses. Antimicrob. Agents Chemother. 41:2256-2260.
6. Cohn, D. L., and M. D. Iseman. 1993. Treatment and prevention of multi-drug-resistant tuberculosis. Res. Microbiol. 144:150-153.
7. Grassi, C. 1997. New drugs for tuberculosis. Exp. Opin. Invest. Drugs 6:1211-1226.
8. Hart, C. A., N. J. Beeching, and B. I. Duerden. 1996. Tuberculosis into the next century. J. Med. Microbiol. 44:1-34.
9. Hoffner, S. E., L. Genzelius, and B. Olsson-Liljequist. 1997. In-vitro activity of fluorinated quinolones against drug-resistant Mycobacterium tuberculosis. J. Antimicrob. Chemother. 40:885-888.
10. Hooper, D. C., and J. S. Wolfson. 1985. The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans. Antimicrob. Agents Chemother. 28:716-721.
11. Ji, B., N. Lounis, C. Truffot-Pernot, and J. Grosset. 1995. In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 39:1341-1344.
12. Kent, P. T., and G. P. Kubica. 1985. Public health mycobacteriology: a guide for the level III laboratory. Centers for Disease Control, Atlanta, Ga.
13. Klemens, S. P., C. A. Sharpe, M. C. Rogge, and M. H. Cynamon. 1994. Activity of levofloxacin in a murine model of tuberculosis. Antimicrob. Agents Chemother. 38:1470-1479.
14. McDonough, K. A., and Y. Kress. 1995. Cytotoxicity for lung epithelial cells is a virulence-associated phenotype of Mycobacterium tuberculosis. Infect. Immun. 63:4802-4811.
15. Oh, Y.-K., and R. M. Straubinger. 1996. Intracellular fate of Mycobacterium avium: use of dual-label spectrofluorometry to investigate the influence of bacterial viability and opsonization of phagosomal pH and phagosome-lysosome interaction. Infect. Immun. 64:319-325.
16. Rastogi, N., K. E. Goh, A. Bryskier, and A. Devallois. 1996. In vitro activities of levofloxacin used alone and in combination with first- and second-line antituberculous drugs against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 40:1610-1616.
17. Saito, H., K. Sato, H. Tomioka, and S. Dekio. 1995. In vitro antimycobacterial activity of a new quinolone, levofloxacin (DR-3355). Tuberc. Lung Dis. 76:377-380.
18. Sato, K., T. Akaki, and H. Tomioka. 1998. Antimicrobial activities of benzoxazinorufamycin KRM-1648, clarithromycin, and levofloxacin against intracellular Mycobacterium avium complex phagocytosed by murine preitoneal macrophages. J. Antimicrob. Chemother. 41:77-83.
19. Sato, K., and H. Tomioka. 1999. Antimicrobial activities of benzoxazinorifamycin (KRM-1648) and clarithromycin against Mycobacterium avium-intracellulare complex residing in murine peritoneal macrophages, human macrophage-like cells and human alveolar epithelial cells. J. Antimicrob. Chemother. 43:351-357.
20. Tomioka, H., K. Sato, T. Akaki, H. Kajitani, S. Kawahara, and M. Sakatani. 1999. Comparative in vitro antimicrobial activities of the newly synthesized quinolone HSR-903, sitafloxacin (DU-6859a), gatifloxacin (AM-1155), and levofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex. Antimicrob. Agents Chemother. 43:3001-3004.
21. Tomioka, H., K. Sato, T. Hidaka, and H. Saito. 1997. In vitro and in vivo antimycobacterial activities of KRM-1648, a new benzoxazinorifamycin, p. 37-68. In S. G. Pandalai (ed.), Recent research developments in antimicrobial agents and chemotherapy. Research Signpost, Trivandrum, India.
22. Tomioka, H., K. Sato, H. Saito, and Y. Yamada. 1989. Susceptibility of Mycobacterium avium and Mycobacterium intracellulare to various antibacterial drugs. Microbiol. Immunol. 33:509-514.
23. Young, L. S. 1996. Mycobacterial infections in immunocompromised patients. Curr. Opin. Infect. Dis. 9:240-245.